icd-10 code for history of statin intolerance

Full Answer

What is the ICD-10 code for adverse effect of statin?

Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter. T46. 6X5A is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.

What is statin intolerance?

As the name suggests, statin intolerance occurs when a patient is unable to continue to use a statin, either because of the development of a side effect or because of evidence on a blood test that certain markers of liver function or muscle function (creatine kinase) are sufficiently abnormal to cause concern. 2.

What is the ICD-10 code for medication intolerance?

ICD-10-CM Code for Unspecified adverse effect of drug or medicament T88. 7.

What is the ICD-10 code for statin induced myalgia?

ICD-10 code G72. 0 for Drug-induced myopathy is a medical classification as listed by WHO under the range - Diseases of the nervous system .

How do you manage statin intolerance?

Statin intolerance has been effectively managed either by the use of alternate-day statin regimen with longer half lives like atorvastatin and rosuvastatin, combination of statins with non-statins, dietary interventions, or by specific pharmacotherapies.

Can you develop statin intolerance?

Statins are one of the most prescribed medications. They help prevent cardiovascular disease so that patients live longer and healthier lives. Yet, some people develop a statin intolerance that makes the medication ineffective.

How do you code adverse effects of drugs?

When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug (T36-T50).

What is drug intolerance?

Drug intolerance or drug sensitivity refers to an inability to tolerate the adverse effects of a medication, generally at therapeutic or subtherapeutic doses. Conversely, a patient is said to be "tolerating" a drug when they can tolerate its adverse effects.

What is the ICD-10 code for medication management?

ICD-10-PCS GZ3ZZZZ is a specific/billable code that can be used to indicate a procedure.

What is statin induced myopathy?

Statin-induced myopathy brings on muscle-related symptoms that didn't exist prior to when you started taking a statin. Symptoms tend to start soon after you begin statin therapy. The disorder may include any or all of the following symptoms: muscle pain. muscle weakness.

What is the diagnosis for ICD 10 code r50 9?

9: Fever, unspecified.

What is drug induced myopathy?

A drug-induced, or toxic, myopathy is defined as the acute or subacute manifestation of myopathic symptoms such as muscle weakness, myalgia, creatine kinase elevation, or myoglobinuria that can occur in patients without muscle disease when they are exposed to certain drugs.

What is T46 poisoning?

T46- Poisoning by , adverse effect of and underdosing of agents primarily affecting the cardiovascular system

What is the secondary code for Chapter 20?

Use secondary code (s) from Chapter 20, External causes of morbidity, to indicate cause of injury. Codes within the T section that include the external cause do not require an additional external cause code. Type 1 Excludes.

What is the code for malabsorption?

Malabsorption due to intolerance to fat. Malabsorption due to intolerance to protein. Malabsorption due to intolerance to starch. The following code (s) above K90.49 contain annotation back-references.

When will the ICD-10-CM K90.49 be released?

The 2022 edition of ICD-10-CM K90.49 became effective on October 1, 2021.

How much statin intolerance is there?

Estimates of statin intolerance from clinical and real-world settings range widely, between 5%-25%, which may be due to the lack of a universally accepted definition or management strategy to address its occurrence.

What are the two types of statin intolerance?

The previously validated ACD algorithm identified 2 types of statin intolerance over 2 years after initiating a statin ( Figure 1 ): (1) absolute statin intolerance, including with and without rhabdomyolysis, and (2) dose titration statin intolerance. To be classified as having absolute statin intolerance with rhabdomy-olysis, patients were required to (a) stop filling a prescription for a single statin; (b) have a medical claim for rhabdomy-olysis; (c) have no additional prescription fills for a statin after the adverse event (i.e., rhabdomyolysis); and (d) have at least 100 days left in the study period. 20 Absolute statin intolerance without rhabdomyolysis was similarly defined, except patients were required to stop filling at least 2 different statins, and adverse events other than rhabdomyolysis (e.g., creatinine kinase tests, myalgia/myositis, arthralgia, myopathy, other muscle toxicity, nausea, constipation, diarrhea, other gastrointestinal distress, anaphylaxis, rash/facial flushing, and cognitive impairment) were included.

How many patients were evaluated for statin intolerance?

RESULTS: After applying the inclusion criteria, 7,490 patients were evaluated for statin intolerance. The mean (SD) age of the population was 51.1 (8.5) years, and 55.7% were male. The MP and ACD algorithms classified 11.3% and 5.4% of patients as having statin intolerance, respectively. The concordance of the MP algorithm was mixed, with negative classification of statin intolerance measures having high concordance (specificity 0.91, NPV 0.97) and positive classification of statin intolerance measures having poor concordance (sensitivity 0.45, PPV 0.21). Overall performance measures showed mixed agreement between the algorithms.

What is a dose titration statin intolerance?

Dose titration statin intolerance was defined similarly to absolute statin intolerance, except that patients were required to first stop filling a high-intensity statin, subsequently fill a lower intensity statin, and then have no fills for another high-intensity statin.

How effective are statins?

Statins have been shown to decrease cardiovascular events in patients with elevated LDL-C and be cost-effective in patients with a wide range of cardiovascular risk factors . 6, 25 - 27 However, despite the abundance of evidence demonstrating the benefits of statins, adherence to statin treatment decreases over time and remains poor (approximately 25% of patients are considered adherent at 5 years after initiation), 28, 29 and up to 25% of patients experience muscle-related symptoms or statin intolerance. 7, 11, 12 For patients with poor adherence, health care systems and providers can undertake efforts to improve statin adherence. Still, cardiovascular risk management of patients with statin intolerance remains difficult and approaches may include increased consultation with the patient, rechallenging statins, use of suboptimal statin doses, alternative statin dosing regimens, and/or use of nonstatin lipid-lowering alternatives. 1, 30

What is the purpose of statins?

In 2013, the guideline from the American College of Cardiology and American Heart Association (ACC/AHA) recommended the use of HMG-CoA reductase inhibitors (statins) to treat blood cholesterol and reduce the risk of cardiovascular events . 1 This guideline shifted from the traditional “treat-to-target” approach for management of low-density lipoprotein cholesterol (LDL-C) and instead focused on the importance of statin use. The guideline recommended a patient-centric focus based on factors such as age, diagnosis of atherosclerotic cardiovascular disease (ASCVD), LDL-C laboratory values, comorbidities and cardiovascular event risk, and corresponding treatment with an appropriate intensity of statins. 1 Because evidence demonstrates that low adherence to or discontinuation of statins because of lack of efficacy or intolerance leads to increased mortality and cardiovascular events, 2 - 5 the guideline also stresses the importance of adherence to statins. 1

Why do people stop taking statins?

In clinical trials, approximately 6% of patients discontinued statins because of statin-associated adverse effects, but this varied depending on the type of statin evaluated. 7, 8 However, the clinical trial estimates may be lower than those seen in real-world settings, since many trials excluded patients with previous adverse events while on a statin and patients at risk of adverse events (e.g., older adults and those with comorbidities). Studies in real-world settings have estimated that 5%-25% of patients may experience muscle-related symptoms or statin intolerance. 11 - 13